NL-OMON42813已完成不适用
A Phase 1 Randomized, Placebo-Controlled, Double-Blind, First- Time-in-Humans, Single-Ascending Dose (SAD) and Multiple- Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CNM-Au8 in Healthy Male and Female Volunteers - Safety, tolerability, PK and PD of CNM-Au8
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.
- •2. Is between the ages of 18 and 45 years, inclusive.
- •3. Females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agree, from the time of signing the informed consent or 14 days prior to check-in until 30 90 days after Study Completion/Discharge, to use two forms of contraception.
- •4. Has a body mass index (BMI) between 18 and 34 kg/m2.
- •5. All laboratory values at screening fall within normal range or are evaluated as not clinically significant (NCS) by the Investigator if outside normal range.
- •6. Has no clinically significant abnormal findings during pre-dose physical examination or
- •Screening and Baseline vital signs or ECG.
- •7. Has not consumed and agrees to abstain from taking any dietary supplements or non- prescription drugs (except as authorized by the Investigator AND Medical Monitor) for 3 days prior to CRU admission through Follow-Up.
- •8. Has not consumed and agrees to abstain from taking any prescription drugs (except as authorized by the Investigator AND Medical Monitor) during the 14 days prior to CRU admission through Follow-Up.
- •9. Has not consumed alcohol-containing beverages for starting 3 days prior to CRU admission and agrees not to consume alcohol through Follow-Up.
- •10. Has not consumed grapefruit or grapefruit juice within the 14 days prior to CRU
- •admission and agrees not to consume grapefruit or grapefruit juice through Follow-Up.
- •11. Has not used tobacco- and nicotine-containing products within 60 days prior to the CRU admission and agrees to abstain from using tobacco- and nicotine-containing products through Follow-Up.
- •12. Has the ability to understand the requirements of the study and is willing to comply with all study procedures.
排除标准
- •1. Has a history of illicit drug abuse in the past year or current evidence of such abuse in the opinion of the Investigator.
- •2. Has positive findings on urine drug screen.
- •3. Is positive for human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C on screening assessments.
- •4. Is pregnant or lactating.
- •5. Has clinically significant medical or psychiatric history that, in the Investigator*s judgment, would compromise the subject*s safety or the collection of data.
- •6. Has donated plasma within 7 days of CRU admission.
- •7. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
- •8. Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year
研究者
相似试验
尚未招募
1 期
A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and ElvitegravirPACTR202310819162115CONRAD20
已完成
1 期
Study in healthy volunteers of the safety and how the body handles PCN-101Mental Health - DepressionDepressionACTRN12620000226909PERCEPTION NEUROSCIENCE, INC.58
进行中（未招募）
不适用
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMetastatic breast cancerEUCTR2007-005949-38-CZAbbott GmbH & Co. KG90
进行中（未招募）
不适用
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMetastatic breast cancerEUCTR2007-005949-38-BEAbbott GmbH & Co. KG90
进行中（未招募）
1 期
Randomized, multicenter study testing the safety and effectiveness of the investigational drug TAK-875 Fasiglifam administered once or twice daily in subjects with type 2 diabetes.MedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 diabetes mellitus (T2DM)MedDRA version: 14.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000886-35-SKTakeda Development Centre Europe Ltd.400